Some naturally occurring fatty acids in animals

Phospholipases hydrolyze phospholipids

- PLA2 will hydrolyze an arachidonate from the carbon-2 position of a membrane phospholipid in an immune response

Arachidonic acid is a precursor to eicosanoids,multi-functional hormones

Prostaglandins, Thromboxanes, and Leukotrienes

Eicosanoids- Eicosanoids are oxygenated derivatives of C20 polyunsaturated

fatty acids (e.g. arachidonic acid)- mediate many pathological responses

20:4D5,8,11,14

Prostaglandin E2 – can cause constriction of blood vessels

EicosanoidsThromboxane A2 – involved in blood clot formation

Leukotriene D4 – mediator of smooth-muscle contraction and provokes bronchial constriction seen in asthmatics.

Aspirin alleviates pain, fever, and inflammation by inhibiting cyclooxygenase (COX), an enzyme critical for the synthesis of Prostaglandins. (NSAID family of compounds)

Advil (Ibuprofen)

An inhibitor of mammalianeicosanoid hormone synthesis

Cyclooxygenase (COX) has two well-studied isoforms, called COX-1 and COX-2. COX-1 mediates the synthesis of prostaglandins responsible for protection of the stomach lining, while COX-2 mediates the synthesis of prostaglandins responsible for pain and inflammation. By creating “selective” NSAIDs that inhibit COX-2, but not COX-1, the same pain relief as traditional NSAIDs is offered, but with greatly reduced risk of fatal or debilitating peptic ulcers. Rofecoxib is a selective COX-2 inhibitor or coxib (CycloOXygenase-2 Inhibitors).

Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. It was marketed by Merck & Co. to treat osteoarthritis and acute pain conditions. Rofecoxib was approved as safe and effective by the Food and Drug Administration (FDA) on May 20, 1999, and was subsequently marketed under the brand names Vioxx, Ceoxx, and Ceeoxx.

Rofecoxib gained widespread acceptance among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time.

On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use. Rofecoxib was one of the most widely used drugs ever to be withdrawn from the market. In the year before withdrawal, Merck had sales revenue of $2.5 billion from Vioxx.